Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
GlobeNewswire
FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine..
Regulatory T cell
News and Video Search Results
News coverage
-
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
GlobeNewswire
-
Viral Vectors & Plasmid DNA Manufacturing Market Size to Exceed USD 23.7 Bn by 2033
GlobeNewswire
-
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
GlobeNewswire
-
2-Day Online Process Validation Guidance Requirements Course: July 25-26, 2024 (FDA and EU Annex 15: Qualifications and Validation)
GlobeNewswire
0 shares
1 views
You might like
Regulatory T cell media coverage
Battery Chemistries in Electric Two-wheelers Strategic Analysis and Growth Opportunities: Increasing Second-life Use Cases for Electric Two-wheeler Batteries
GlobeNewswire
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Strategic Analysis of Battery Chemistries in Electric Two-wheelers and Growth..
-
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
-
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
-
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
GlobeNewswire
-
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
GlobeNewswire
Advertisement
More coverage
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
GlobeNewswire
· Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients..
-
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
-
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
GlobeNewswire
-
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
-
Global Hydrogen Vehicle Market Set to Exceed $28 Billion in 2024
GlobeNewswire